Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.

@article{Johannsson2012ImprovedCE,
  title={Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.},
  author={Gudmundur Johannsson and Anna G. Nilsson and Ragnhildur Bergthorsdottir and Pia Burman and Per Dahlqvist and Bertil Ekman and Britt Ed{\'e}n Engstr{\"o}m and Tommy Olsson and Oskar Ragnarsson and Marianne Ryberg and Jeanette Wahlberg and Beverly M. K. Biller and John P. Monson and P. M. Stewart and Hans Lennernaes and Stanko Skrtic},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2012},
  volume={97 2},
  pages={473-81}
}
CONTEXT Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile. OBJECTIVE The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets. DESIGN AND SETTING We conducted an open, randomized, two… CONTINUE READING